×
English
हिंदी
ગુજરાતી
Home
My Feed
Remove Ads
Get Premium Content
Go Pro @₹99
Loan Against Mutual Fund
Apply Now
Credit Cards
Instant Loans
Apply Now
Credit Score
Refer & Earn ₹500
Refer Now
Finance Tracker
Learning Curve
Fixed Deposits
Business Loan
Vouchers
Markets
Markets
FII & DII Activity
Corporate Action
Research Advice
Earnings
Technical Trends
Stock Deals
Intraday Large Deals
Bonds
Webinar
Pre Market
Stock Scanner
Sector Analysis
Unlisted Shares
Stock Updates
PRO Stock Lists
Monsoon Tracker
Seasonality Analysis
Crypto Dashboard
Web Stories
Tax Calculator
Forum
Gold Rate
Silver Rate
IFSC Code Finder
Storyboard18
IPO
Economic Indicators
Economic Calendar
Global Markets
US Markets
ETFs
Indian Indices
News
News
Tech/Startups
Auto
Research
Opinion
Politics
Personal Finance
EPF Guide
Real Estate
Portfolio
Watchlist
Personal Finance
Personal Finance
Loans
Fixed Deposit Comparison
Fixed Deposit Interest Calculator
Moneycontrol - SecureNow Health Insurance ratings
Mutual Funds
Mutual Funds
Performance Tracker
Top ranked funds
My Portfolio
Top performing Categories
Forum
New Fund Offers
MF Simplified
Commodities
Mutual Funds
Gold Rate
Silver Rate
Currencies
Cryptocurrency
Media
Live TV & Shows
Video
Podcast
Photos
Invest Now
Trade like Experts
Invest in Unlisted Shares
Specials
Pharma Industry Conclave
Unlocking opportunities in Metal and Mining
#MFSummit2025
Advanced Technical Charts
International
Get App
Be a
Pro
Home
PRO
Markets
News
Budget 2026
Editor’s Picks
Tech
India
Learning Curve
Portfolio
Watchlist
Commodities
MF
PF
Forum
Videos
you are here:
Home
News
Crams
Crams
What does the new US Biosecure draft Act mean for the Indian CRDMO industry?
Sai Life Sciences: Strong start keeps CDMO business in the lead
Syngene: How soon can it overcome near-term worries?
Syngene: US acquisition underlines welcome tweak in business model
Syngene: Conversion of pilot projects to long-term contracts a big positive
Syngene: Strong play on ‘China Switches’ in the CRAMS space
Syngene: The preferred pick for sector re-allocation
PI Industries: New products, pharma to define medium-term growth
Weekly Tactical Pick: China+1 trend to enhance earnings visibility for this CRAMS player
Growth momentum intact at PI Industries
Syngene: Preferred CRAMS play for the long term
Syngene: Stock correction serves as an opportunity to move in
Syngene: Inorganic initiative to speed up biologics manufacturing bandwidth
PI Industries: Volume-led growth to continue for this richly-valued stock
Laurus Labs: Is the worst priced in?
Syngene: Timeline for follow-through in Zoetis contract key catalyst to watch
Laurus Labs Q2: What worked, what didn't?
Syngene: Can it keep its premium valuation, going forward?
Hikal: Is the worst over?
Laurus Labs: Diversification picks up pace
Navin Fluorine: Diversification away from agrochemicals to set it apart
Syngene: Multi-year contract with Zoetis adds to long-term visibility
Laurus Labs: This pharma stock gets a shot in the arm
Divi’s Labs: Steady margin profile amid cost headwind
Aether IPO | This niche chemical player is a leader of the pack. How?
View More
Home
Markets
Loans
SPIN
2
WIN
News
Portfolio